| Description |
1 online resource (1 PDF file (xii, 45 pages)) : illustrations |
| Contents |
Cover -- Copyright -- Table of Contents -- Preface -- Acknowledgments -- REVIEWERS -- Executive Summary -- PROJECT-SPECIFIC FINDINGS AND RECOMMENDATIONS -- NCID-Directed Projects in the Research Program -- NIP-Directed Projects of the Research Program -- 1 Introduction and Background -- ANTHRAX DISEASE AND PREVENTION -- Anthrax Disease -- Anthrax Vaccine -- VACCINE RELATED ADVERSE EVENTS -- POLICY CONTEXT OF REPORT -- Anthrax Vaccination Policy -- CDC'S REPONSE TO CONGRESS -- 2 Interim Findings and Recommendations -- NCID RESEARCH ACTIVITIES -- Part A: Clinical Trial -- Part B: Non-human Primate Dose-Ranging and Challenge Study -- Part C: Assays of Immunologic Correlates of Protection -- NIP RESEARCH ACTIVITIES -- Knowledge, Attitudes, and Beliefs of Military Personnel about the Anthrax Vaccine -- Knowledge, Attitudes, and Beliefs of Vaccine Providers about VAERS Reporting -- Data Mining Using the VAERS Database -- Meta-Analysis of Existing Studies on the Anthrax Vaccine -- REFERENCES -- ACRONYMS -- Appendix A Study Activities |
| Summary |
Anthrax in its inhalational form is a deadly but very rare manifestation of infection with a common organism, Bacillus anthracis. Anthrax spores are very stable, a characteristic that makes possible their delivery as a weapon of biological warfare, and examples of weapons development efforts using anthrax are well known. It is important to protect the men and women in our armed services to the greatest extent possible. The Department of Defense (DoD) established the Anthrax Vaccine Immunization Program (AVIP) in order to do so; however, some parties have raised questions about the safety and even the efficacy of the vaccine. As a result, the DoD is sponsoring an Institute of Medicine (IOM) study of the safety and efficacy of the vaccine, and Congress has instructed the Centers for Disease Control and Prevention (CDC) to conduct further safety and efficacy research. The CDC contracted with the IOM to review their research program for completeness and appropriateness. This document is an interim report of the Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program, and reflects only a preliminary review of a program still in development |
| Notes |
Title from PDF title page |
|
"Prepublication Copy, Uncorrected Proofs"--PDF title page |
| Bibliography |
Includes bibliographical references |
| Notes |
Support for this project was provided by the Centers for Disease Control and Prevention, Department of Health and Human Services (Contract No. 200-2000-00629). The views presented in this report are those of the Institute of Medicine Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program and are not necessarily those of the funding agencies |
|
Version viewed December 23, 2014 |
| SUBJECT |
Centers for Disease Control and Prevention (U.S.) |
| Subject |
Anthrax -- Vaccination.
|
|
Vaccines -- Effectiveness
|
|
Vaccines -- Safety measures
|
|
Anthrax Vaccines
|
|
Anthrax -- prevention & control
|
|
Drug Evaluation
|
|
Program Evaluation
|
|
MEDICAL -- Infectious Diseases.
|
|
HEALTH & FITNESS -- Diseases -- Contagious.
|
|
Anthrax -- Vaccination
|
|
Vaccines -- Safety measures
|
| SUBJECT |
United States https://id.nlm.nih.gov/mesh/D014481 |
| Form |
Electronic book
|
| Author |
Institute of Medicine (U.S.). Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program, author.
|
| ISBN |
0309579872 |
|
9780309579872 |
|
1280248041 |
|
9781280248047 |
|
